Abstract:BACKGROUND:Malignant pleural effusion is one of the common clinical manifestations of patients with lung adenocarcinoma. Patients with pleural effusion at the initial diagnosis of lung adenocarcinoma usually indicate poor prognosis. Epidermal growth factor receptor (EGFR) mutations mainly occur in patients with lung adenocarcinoma. Patients with different mutant subtypes have different prognosis. The clinical characteristics and prognostic factors of patients with EGFR mutated lung adenocarcinoma of different molecular subtypes combined with pleural effusion at initial diagnosis are still unclear. This study was designed to explore the clinical characteristics and prognostic factors of these patients in order to provide management recommendations for them. METHODS:A retrospective analysis of the clinical characteristics, treatment, outcomes and progression-free survival (PFS) of first-line treatment in patients with EGFR mutated lung adenocarcinoma combined with pleural effusion at initial diagnosis admitted to Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital from January 2012 to June 2021 was performed. Pearson's chi-square test or Fisher's exact test were performed for comparison between groups. Kaplan-Meier method was performed for survival analysis and Cox proportional risk regression model was performed for multivariate analysis. RESULTS:76 patients met the inclusion criteria in this study. The incidences of EGFR classical mutations 19del, 21L858R and non-classical mutations were 46.0%, 38.2% and 15.8%, respectively among these patients. There was no significant difference between the three mutations in terms of gender, age, presence of dyspnea at presentation, whether other distant metastases were combined, site of pleural effusion, volume of pleural effusion, presence of other combined effusions, tumor-node-metastasis (TNM) stage, presence of other gene mutations, and treatment of pleural effusion (P>0.05). In patients with EGFR classical mutations 19del or 21L858R or non-classical mutations subtype, the proportion of chemotherapy in first-line regimens were 17.1%, 20.7% and 58.3%, respectively (P=0.001); and first-line disease control rates were 94.3%, 75.9% and 50%, respectively (P=0.003); pleural effusion control rates were 94.3%, 79.3% and 66.7%, respectively (P=0.04); PFS were 287 d, 327 d and 55 d, respectively (P=0.001). Univariate analysis showed that EGFR mutation subtype, control of pleural effusion, first-line treatment agents, and first-line treatment efficacy were significantly associated with PFS (P<0.05). Cox multifactorial analysis showed that only EGFR mutation subtype and first-line treatment efficacy were independent prognostic factors for PFS (P<0.05). CONCLUSIONS:PFS was significantly better for classical mutations than for non-classical mutations in patients with EGFR mutated lung adenocarcinoma combined with pleural effusion at initial diagnosis. Improving the efficacy of first-line therapy is the key to improve the prognosis of these patients.

P3.01-025 Treatment Outcomes of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status: A Retrospective Analysis of 140 Patients

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

A Prospective Comparison Study on EGFR Mutations by Direct Sequencing and ARMS in Completely Resected Chinese Non-Small Cell Lung Cancer with Adenocarcinoma Histology (ICAN).

Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study

Efficacy and Predictors of Egfr Tyrosine Kinase Inhibitors in Chinese Advanced Lung Adenocarcinoma: Analyses of 253 Cases from A Single Institute

Superior Efficacy of Immunotherapy‐based Combinations over Monotherapy for EGFR‐mutant Non‐small Cell Lung Cancer Acquired Resistance to EGFR‐TKIs

Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma

Egfr Mutation and Survival Outcomes in Patients with Completely Resected Lung Adenocarcinoma – a Multiple Centers, Non-Interventional Study (ican Trial)

EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis

CTONG1104: Adjuvant Gefitinib Versus Chemotherapy for Resected N1-N2 NSCLC with EGFR Mutation-Final Overall Survival Analysis of the Randomized Phase III Trial 1 Analysis of the Randomized Phase III Trial.

P3.02-068 95 Cases of EGFR/ALK Gene Status Analysis in Lung Adenosquamous Carcinoma

A PROSPECTIVE, MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH ADENOCARCINOMA HISTOLOGY (PIONEER STUDY) - CHINA SUBSET ANALYSIS

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study

Does Neoadjuvant Targeted Therapy Provide an Opportunity for Resectable EGFR-mutant Lung Cancer: a Real-World Retrospective Study

A Multicenter Survey of First-Line Treatment Patterns and Gene Aberration Test Status of Patients with Unresectable Stage IIIB/IV Nonsquamous Non-Small Cell Lung Cancer in China (CTONG 1506)

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis

Clinical Characteristics and Prognosis of 76 Lung Adenocarcinoma Patients Harboring EGFR Mutations with Pleural Effusion at Initial Diagnosis: A Single-center Retrospective Study